New Peptide Compounding Policy: What Changed for Hawaiʻi Patients?
Six peptides are at the center of a new federal compounding policy. If you saw the headlines today and wondered what changed, here is where I would start.
For people in Hawaiʻi following BPC-157, TB-500, or other peptides, the latest federal announcement is worth understanding. A change in access can be meaningful even when it does not answer every question about a treatment.
Here is my plain-language reading of the documents available on October 29, 2026.
What changed this week?
HHS has posted an interim enforcement-discretion policy for certain patient-specific compounded peptides while FDA works through its formal rulemaking process. The Federal Register notice calls it a draft policy and is scheduled for publication October 30. It is not a final addition to the 503A bulks list.
Which six peptides are included?
The policy lists BPC-157, TB-500, MOTS-c, KPV, Epitalon, and Semax. Its conditions apply to specified forms and routes, not every product carrying those names.
Did the FDA approve these peptides?
No. This is a compounding enforcement policy, not FDA approval of six new drugs. That distinction matters when reading a headline or deciding what questions to ask about a particular product.
What does “enforcement discretion” mean?
In this context, HHS says it does not intend to take enforcement action against qualifying compounders when the policy’s conditions are met. Those conditions include patient-specific prescriptions, sourcing and quality requirements, reporting, and single-active-ingredient products. HHS can revisit the policy if concerns arise.
Does that include BPC-157 and TB-500 blends?
The policy specifies a single active ingredient. Its listing of both peptides should not be read as coverage for a combined “stack.”
What does this mean for someone in Hawaiʻi?
My starting point would be the person’s goal. What are they hoping will improve? What diagnosis or symptom are we addressing? What have they already tried? A product name is not enough to answer those questions.
From there, I would want to discuss the evidence for that specific use, the exact formulation and pharmacy, potential risks, and how we would judge whether treatment was helping. Local availability and a thoughtful treatment decision are separate questions.
This is also where the conversation can get lost online. A person asking about an injury, someone interested in metabolism, and someone curious about longevity may all search the word “peptides.” They are not necessarily asking about the same treatment—or the same quality of evidence.
Does a policy change mean the treatment works?
A policy announcement cannot settle that question for an individual patient. I want to know what was studied, whether the research involved people, which formulation was used, and what outcomes were measured. A biological explanation can be interesting without telling us how much benefit a person should expect.
What should you ask before considering a peptide?
Start with these questions: What is the proposed use? What human evidence supports it? What are the uncertainties and alternatives? Which pharmacy would prepare it? What follow-up would be needed, and what would make us stop?
Those questions make room for curiosity while keeping the discussion specific. They are more useful than treating every peptide as either a breakthrough or something to dismiss.
Where I’m taking this series
I’ll be looking at these peptides individually, beginning with BPC-157 and TB-500, then working through MOTS-c, KPV, Semax, and Epitalon. I want each article to answer the questions a reader would actually bring to an appointment.
For now, the news gives us a reason to look more closely. The next step is to look at each substance—and the evidence behind it—on its own.
Comments